Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

NCT05093517 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Glucose Tolerance Impaired
Insulin Sensitivity

Interventions

DRUG: REMD-477
DRUG: Placebo Subcutaneous injection

Sponsor

The University of Texas Health Science Center at San Antonio